Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Assets (2016 - 2026)

United Therapeutics' Assets history spans 17 years, with the latest figure at $7.9 billion for Q4 2025.

  • On a quarterly basis, Assets rose 7.01% to $7.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.9 billion, a 7.01% increase, with the full-year FY2025 number at $7.9 billion, up 7.01% from a year prior.
  • Assets hit $7.9 billion in Q4 2025 for United Therapeutics, up from $7.4 billion in the prior quarter.
  • Over the last five years, Assets for UTHR hit a ceiling of $7.9 billion in Q2 2025 and a floor of $4.6 billion in Q1 2021.
  • Historically, Assets has averaged $6.4 billion across 5 years, with a median of $6.6 billion in 2023.
  • Biggest five-year swings in Assets: grew 21.48% in 2023 and later increased 0.63% in 2024.
  • Tracing UTHR's Assets over 5 years: stood at $5.2 billion in 2021, then rose by 16.94% to $6.0 billion in 2022, then increased by 18.57% to $7.2 billion in 2023, then increased by 2.75% to $7.4 billion in 2024, then increased by 7.01% to $7.9 billion in 2025.
  • Business Quant data shows Assets for UTHR at $7.9 billion in Q4 2025, $7.4 billion in Q3 2025, and $7.9 billion in Q2 2025.